{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T10:55:51Z","timestamp":1774608951622,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T00:00:00Z","timestamp":1138752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2006,2]]},"DOI":"10.1053\/j.seminoncol.2005.12.020","type":"journal-article","created":{"date-parts":[[2006,3,3]],"date-time":"2006-03-03T12:24:32Z","timestamp":1141388672000},"page":"26-32","source":"Crossref","is-referenced-by-count":6,"special_numbering":"S3","title":["Clinical Experience: Practical Management of Five Patients With Cutaneous T-Cell Lymphoma (CTCL)-Related Symptoms"],"prefix":"10.1053","volume":"33","author":[{"given":"Reinhard","family":"Dummer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francine","family":"Foss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Dreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martine","family":"Bagot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2005.12.020_bib1","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1159\/000072098","article-title":"Therapy of cutaneous lymphoma-current practice and future developments","volume":"26","author":"Dummer","year":"2003","journal-title":"Onkologie"},{"key":"10.1053\/j.seminoncol.2005.12.020_bib2","first-page":"3578","article-title":"Prospective randomized multicenter clinical trial on the use of interferon-2a plus acitretin versus interferon-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II","volume":"92","author":"Stadler","year":"1998","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2005.12.020_bib3","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1182\/blood-2002-08-2455","article-title":"Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells","volume":"102","author":"Maier","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2005.12.020_bib4","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1182\/blood-2004-01-0360","article-title":"Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas","volume":"104","author":"Dummer","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2005.12.020_bib5","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma","volume":"19","author":"Duvic","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2005.12.020_bib6","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jaad.2003.05.010","article-title":"Cutaneous T-cell lymphoma treatment using bexarotene and PUVA","volume":"51","author":"Singh","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1053\/j.seminoncol.2005.12.020_bib7","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000078595","article-title":"Combination of bexarotene and psoralen-UVA therapy in a patient with Mycosis fungoides","volume":"209","author":"Michaelis","year":"2004","journal-title":"Dermatology"},{"key":"10.1053\/j.seminoncol.2005.12.020_bib8","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1182\/blood-2002-01-0300","article-title":"Immunomodulatory effects of RXR rexinoids","volume":"100","author":"Gorgun","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2005.12.020_bib9","doi-asserted-by":"crossref","unstructured":"Porcu P, Baiocchi R, Buckner M, et al: Bexarotene-induced T-cell immunomodulation an response in CTCL. Blood 104:744, 2004 (abstr)","DOI":"10.1182\/blood.V104.11.744.744"},{"key":"10.1053\/j.seminoncol.2005.12.020_bib10","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1182\/blood.V97.5.1388","article-title":"CD4+ cutaneous T-cell lymphoma cells express the p140-killer cell immunoglobulin-like receptor","volume":"97","author":"Bagot","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2005.12.020_bib11","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0190-9622(96)90119-X","article-title":"Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa","volume":"35","author":"Gottlieb","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1053\/j.seminoncol.2005.12.020_bib12","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma","volume":"19","author":"Duvic","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2005.12.020_bib13","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1749-6632.2001.tb03727.x","article-title":"Pegylated doxorubicin for primary cutaneous T cell lymphoma","volume":"941","author":"Wollina","year":"2001","journal-title":"Ann N Y Acad Sci"},{"key":"10.1053\/j.seminoncol.2005.12.020_bib14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1046\/j.1365-2133.2000.03601.x","article-title":"Treatment of erythrodermic cutaneous T-cell lymphoma with intermittent chlorambucil and fluocortolone therapy","volume":"143","author":"Coors","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1053\/j.seminoncol.2005.12.020_bib15","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0190-9622(89)70251-6","article-title":"Low-dose methotrexate for the Sezary syndrome","volume":"21","author":"Zackheim","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"10.1053\/j.seminoncol.2005.12.020_bib16","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1085-5629(00)80003-6","article-title":"Pathogenesis of cutaneous lymphomas","volume":"19","author":"Dummer","year":"2000","journal-title":"Semin Cutan Med Surg"},{"key":"10.1053\/j.seminoncol.2005.12.020_bib17","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/1523-1747.ep12285617","article-title":"Chromosomal abnormalities in cutaneous T-cell lymphoma and in premalignant conditions as detected by G-banding and interphase cytogenetic methods","volume":"108","author":"Karenko","year":"1997","journal-title":"J Invest Dermatol"},{"key":"10.1053\/j.seminoncol.2005.12.020_bib18","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJM198912283212603","article-title":"A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides","volume":"321","author":"Kaye","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2005.12.020_bib19","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1517\/14728214.10.2.381","article-title":"Emerging drugs in cutaneous T-cell lymphomas","volume":"10","author":"Dummer","year":"2005","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1053\/j.seminoncol.2005.12.020_bib20","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.2105\/AJPH.89.8.1240","article-title":"Twenty year trends in the reported incidence of mycosis fungoides and associated mortality","volume":"89","author":"Weinstock","year":"1999","journal-title":"Am J Public Health"},{"key":"10.1053\/j.seminoncol.2005.12.020_bib21","unstructured":"Office for National Statistics, Cancer Statistics Registrations. Registrations of Cancer Diagnosed in 2000, England. Series MB1, No 31"},{"key":"10.1053\/j.seminoncol.2005.12.020_bib22","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1365-2230.2004.01525.x","article-title":"A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides","volume":"29","author":"Child","year":"2004","journal-title":"Clin Exp Dermatol"},{"key":"10.1053\/j.seminoncol.2005.12.020_bib23","first-page":"1095","article-title":"Joint British Association of Dermatologists and U.K","volume":"149","author":"Whittaker","year":"2003","journal-title":"Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. Br J Dermatol"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775405005142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775405005142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T00:54:33Z","timestamp":1586739273000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775405005142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2]]},"references-count":23,"alternative-id":["S0093775405005142"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2005.12.020","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2006,2]]}}}